ShanX Medtech Raises €24 Million to Fight Antimicrobial Resistance with Female Leadership

Eindhoven-based ShanX Medtech, a MedTech startup, has successfully closed a Seed funding round of €15 million to expand its operations, enhance clinical validation, and prepare for market entry. The funding round, which was oversubscribed, included a variety of funding instruments such as equity, grants, and the Innovatiekrediet. Notable investors in this round included the Borski Fund, NextGen Ventures, CbusineZ, Brabantse Ontwikkelings Maatschappij, Invest-NL, and a strategic angel fund.

Additionally, ShanX Medtech recently secured a €8.85 million European Commission Contract, bringing their total financing to €24 million. Dr. Sophia E. Shanko, the founder and CEO of ShanX Medtech, expressed the company’s mission to provide rapid antibiotic susceptibility testing to clinicians in real-time. The company aims to deliver ultra-rapid AST directly to laboratory and point-of-care environments, making it faster, simpler, and more accessible than current methods.

Founded in 2019 at the High Tech Campus in Eindhoven, ShanX Medtech specializes in developing In-Vitro Diagnostic solutions for antimicrobial susceptibility testing. Their proprietary chemical composition, FLORA™, monitors pathogen metabolism in real-time, allowing for quicker and more user-friendly results compared to traditional methods.

With the recent funding, ShanX Medtech plans to accelerate the final development, clinical validation, regulatory approval, and commercial launch of their diagnostic platform. Simone Brummelhuis, Partner at Borski Fund, praised ShanX’s technology as best-in-class and highlighted the company’s potential in addressing antimicrobial resistance across various clinical indications.

This significant funding round and commercial contracts demonstrate the strength of ShanX Medtech’s technology and the founder’s ability to execute successfully. The company’s innovative approach to antibiotic susceptibility testing has the potential to revolutionize healthcare practices and improve patient outcomes.